Acura Pharmaceuticals, Inc. (OTCMKTS:ACUR) Director Bruce F. Wesson acquired 335,734 shares of the stock in a transaction dated Thursday, December 14th. The shares were bought at an average cost of $0.10 per share, for a total transaction of $33,573.40. Following the acquisition, the director now owns 394,404 shares in the company, valued at approximately $39,440.40. The purchase was disclosed in a legal filing with the SEC, which is accessible through this link.
Acura Pharmaceuticals, Inc. (OTCMKTS:ACUR) traded up $0.09 on Monday, reaching $0.42. The company’s stock had a trading volume of 64,854 shares, compared to its average volume of 17,017. The company has a current ratio of 1.23, a quick ratio of 1.23 and a debt-to-equity ratio of 0.44. Acura Pharmaceuticals, Inc. has a 12-month low of $0.29 and a 12-month high of $1.40.
Acura Pharmaceuticals (OTCMKTS:ACUR) last released its earnings results on Monday, November 13th. The specialty pharmaceutical company reported ($0.12) earnings per share (EPS) for the quarter. The business had revenue of $0.08 million during the quarter. Acura Pharmaceuticals had a negative net margin of 36.20% and a negative return on equity of 231.18%.
Separately, ValuEngine raised Acura Pharmaceuticals from a “strong sell” rating to a “sell” rating in a report on Friday, December 1st.
WARNING: This article was originally posted by Transcript Daily and is the sole property of of Transcript Daily. If you are accessing this article on another publication, it was copied illegally and reposted in violation of US and international copyright & trademark laws. The correct version of this article can be viewed at https://transcriptdaily.com/2017/12/18/acura-pharmaceuticals-inc-acur-director-acquires-33573-40-in-stock.html.
Acura Pharmaceuticals Company Profile
Acura Pharmaceuticals, Inc is a pharmaceutical company. The Company is engaged in the research, development and commercialization of technologies and products intended to address medication abuse and misuse. The Company has discovered and developed three platform technologies, which can be used to develop multiple products.
Receive News & Ratings for Acura Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Acura Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.